Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression.
作者信息
Tembhare Prashant, Yuan Constance, Korde Neha, Maric Irina, Landgren Ola
出版信息
Leuk Lymphoma. 2012 Apr;53(4):721-4. doi: 10.3109/10428194.2011.623257. Epub 2011 Nov 25.
Abstract
摘要
相似文献
1
Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression.复发的髓外多发性骨髓瘤中的抗原性漂移：无CD38表达的浆细胞。
Leuk Lymphoma. 2012 Apr;53(4):721-4. doi: 10.3109/10428194.2011.623257. Epub 2011 Nov 25.
2
CD38 expression by plasma cells in extramedullary multiple myeloma.髓外多发性骨髓瘤中浆细胞的CD38表达
Haematologica. 2024 Apr 1;109(4):1297-1300. doi: 10.3324/haematol.2023.284169.
3
Double CD38/CD138 negative multiple myeloma.双CD38/CD138阴性多发性骨髓瘤
Hematol Oncol Stem Cell Ther. 2019 Mar;12(1):64-66. doi: 10.1016/j.hemonc.2017.08.003. Epub 2017 Oct 18.
4
DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.DNA甲基转移酶抑制剂上调CD38蛋白表达并增强达雷妥尤单抗在多发性骨髓瘤中的疗效。
Leukemia. 2020 Mar;34(3):938-941. doi: 10.1038/s41375-019-0587-5. Epub 2019 Oct 8.
5
CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy.基于达雷妥尤单抗的化疗后多发性骨髓瘤患者出现CD38阴性复发
Eur J Haematol. 2017 Aug;99(2):186-189. doi: 10.1111/ejh.12902. Epub 2017 Jun 6.
6
CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab.CD319（SLAMF7）是一种替代标志物，可用于在达雷木单抗或埃罗妥珠单抗存在的情况下检测浆细胞。
Cytometry B Clin Cytom. 2021 Jul;100(4):497-508. doi: 10.1002/cyto.b.21961. Epub 2020 Oct 5.
7
Myelomatous pleural effusion with plasmablastic morphology and high genetic complexity as isolated extramedullary relapse.具有浆母细胞形态和高遗传复杂性的骨髓瘤性胸腔积液作为孤立性髓外复发。
Ann Hematol. 2020 Nov;99(11):2705-2706. doi: 10.1007/s00277-020-04071-w. Epub 2020 May 27.
8
Clinical and immunological characteristics of high-risk double-hit multiple myeloma.高危双打击多发性骨髓瘤的临床和免疫学特征。
BMC Cancer. 2024 Nov 10;24(1):1373. doi: 10.1186/s12885-024-13124-6.
9
VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months.VS38 鉴定出在达雷妥尤单抗治疗后 CD38 弱表达的骨髓瘤细胞和浆细胞，这会干扰 CD38 检测达 4 至 6 个月。
Am J Clin Pathol. 2020 Jan 2;153(2):221-228. doi: 10.1093/ajcp/aqz153.
10
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.高参数液质联用流式细胞术评估达雷妥尤单抗治疗复发/难治性多发性骨髓瘤患者的疗效，结果表明免疫调节是一种新的作用机制。
Cytometry A. 2019 Mar;95(3):279-289. doi: 10.1002/cyto.a.23693. Epub 2018 Dec 11.
引用本文的文献
1
CAR-T cells in the treatment of multiple myeloma: an encouraging cell therapy.嵌合抗原受体T细胞疗法治疗多发性骨髓瘤：一种令人鼓舞的细胞疗法。
Front Immunol. 2025 Feb 26;16:1499590. doi: 10.3389/fimmu.2025.1499590. eCollection 2025.
2
p53-NEIL1 co-abnormalities induce genomic instability and promote synthetic lethality with Chk1 inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain).p53-NEIL1 共异常诱导基因组不稳定性，并与同时存在 17p13(del) 和 1q21(gain) 的多发性骨髓瘤中的 Chk1 抑制协同导致合成致死。
Oncogene. 2022 Apr;41(14):2106-2121. doi: 10.1038/s41388-022-02227-8. Epub 2022 Feb 21.
3
Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.嵌合抗原受体（CAR）T细胞疗法在多发性骨髓瘤中的新进展。
Stem Cell Investig. 2021 Jan 15;8:1. doi: 10.21037/sci-2020-029. eCollection 2021.
4
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.新型 HDAC6 抑制剂上调多发性骨髓瘤细胞 CD38 表达属类效应，并增强达雷妥尤单抗的疗效。
Leukemia. 2021 Jan;35(1):201-214. doi: 10.1038/s41375-020-0840-y. Epub 2020 Apr 29.
5
CARs and other T cell therapies for MM: The clinical experience.嵌合抗原受体（CAR）及其他用于多发性骨髓瘤的T细胞疗法：临床经验
Best Pract Res Clin Haematol. 2018 Jun;31(2):147-157. doi: 10.1016/j.beha.2018.03.002. Epub 2018 Mar 27.
6
CAR T cell therapy for multiple myeloma: where are we now and where are we headed?嵌合抗原受体T细胞疗法治疗多发性骨髓瘤：我们目前的状况及未来走向？
Leuk Lymphoma. 2018 Sep;59(9):2056-2067. doi: 10.1080/10428194.2017.1393668. Epub 2017 Nov 6.
7
Immunologic approaches for the treatment of multiple myeloma.用于治疗多发性骨髓瘤的免疫疗法
Cancer Treat Rev. 2017 Apr;55:190-199. doi: 10.1016/j.ctrv.2017.03.010. Epub 2017 Apr 6.
8
Immunotherapies targeting CD38 in Multiple Myeloma.靶向多发性骨髓瘤中CD38的免疫疗法。
Oncoimmunology. 2016 Aug 5;5(11):e1217374. doi: 10.1080/2162402X.2016.1217374. eCollection 2016.
本文引用的文献
1
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma.新型疗法时代多发性骨髓瘤患者发生髓外疾病的情况，以及泊马度胺对髓外骨髓瘤的作用。
Leukemia. 2011 Jun;25(6):906-8. doi: 10.1038/leu.2011.29. Epub 2011 Feb 25.
2
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.达雷妥尤单抗，一种新型治疗性人源 CD38 单克隆抗体，可诱导多发性骨髓瘤和其他血液系统肿瘤的杀伤。
J Immunol. 2011 Feb 1;186(3):1840-8. doi: 10.4049/jimmunol.1003032. Epub 2010 Dec 27.
3
Extramedullary plasmacytoma are characterized by a 'myeloma-like' immunophenotype and genotype and occult bone marrow involvement.髓外浆细胞瘤的特征是具有“骨髓瘤样”免疫表型和基因型以及隐匿性骨髓受累。
Br J Haematol. 2010 Dec;151(5):525-7. doi: 10.1111/j.1365-2141.2010.08386.x. Epub 2010 Sep 29.
4
Review: extramedullary disease in multiple myeloma.综述：多发性骨髓瘤的髓外疾病
Clin Adv Hematol Oncol. 2009 Dec;7(12):802-4.
5
Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders.MGUS 和 MM 的流式细胞分析中使用的表型标志物的综述，以及流式细胞术在其他浆细胞疾病中的适用性。
Br J Haematol. 2010 May;149(3):334-51. doi: 10.1111/j.1365-2141.2010.08121.x. Epub 2010 Mar 1.
6
Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders.流式细胞术免疫表型分析在多发性骨髓瘤和其他克隆性浆细胞相关疾病中的应用。
Cytometry B Clin Cytom. 2010 Jul;78(4):239-52. doi: 10.1002/cyto.b.20512.
7
Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection.在诱导 T 细胞淋巴母细胞白血病时，不成熟相关抗原丢失：对微小残留病检测的影响。
Cytometry B Clin Cytom. 2010 May;78(3):139-46. doi: 10.1002/cyto.b.20511.
8
Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study.二十一世纪多发性骨髓瘤患者生存率提高的模式：一项基于人群的研究。
J Clin Oncol. 2010 Feb 10;28(5):830-4. doi: 10.1200/JCO.2009.25.4177. Epub 2009 Dec 28.
9
The significance of tumour cell immunophenotype in myeloma and its impact on clinical outcome.骨髓瘤肿瘤细胞免疫表型的意义及其对临床结局的影响。
J Clin Pathol. 2009 Nov;62(11):1009-15. doi: 10.1136/jcp.2009.065128.
10
Instability of immunophenotype in plasma cell myeloma.浆细胞骨髓瘤中免疫表型的不稳定性
Am J Clin Pathol. 2008 Jun;129(6):926-33. doi: 10.1309/8UVF7YQ1D4D4ETQV.
Zotero 插件